Files in this item
Mechanisms of action of 3’-deoxyadenosine in treating clear cell renal cell carcinoma
Item metadata
dc.contributor.advisor | Harrison, David James | |
dc.contributor.advisor | Melo Czekster, Clarissa | |
dc.contributor.author | Kudsy, Mary | |
dc.coverage.spatial | 225 | en_US |
dc.date.accessioned | 2023-05-22T09:48:56Z | |
dc.date.available | 2023-05-22T09:48:56Z | |
dc.date.issued | 2023-06-12 | |
dc.identifier.uri | https://hdl.handle.net/10023/27660 | |
dc.description.abstract | Although treatment strategies for advanced and metastatic clear cell renal cell carcinoma (ccRCC) have markedly evolved with the recent use of immune-checkpoint inhibitor (ICI)-based combinations, most patients eventually develop resistance to these therapies. Therefore, there is still an urgent need for the development of effective treatment options. NUC-7738, a novel ProTide transformation of the nucleoside analogue 3ﹶ-deoxyadenosine, releases 3ﹶ-deoxyadenosine monophosphate (3’-dAMP) in cells which is then phosphorylated to the di- (3’-dADP) and tri-phosphate forms (3’-dATP). 3’-dAMP might have the ability to activate AMP-activated protein kinase (AMPK), a key cellular energy sensor, and thus disrupt metabolic homeostasis in cancer cells. Furthermore, 3’-dATP might interfere with RNA synthesis affecting protein expression and survival of cancer cells. The ability of NUC-7738 to activate AMPK through phosphorylation of Th172 was tested in ccRCC cell lines and ex vivo tissue slices of ccRCC from patients. The effect of NUC-7738 on mRNA synthesis and polyadenylation was investigated in two ccRCC cell lines, 786-O and 769-P. AMPK activation by NUC-7738 showed inter-replicate variability and inter-patient variability in ccRCC cell lines and ex vivo tissue slices, respectively, indicating the complexity of the regulation of AMPK phosphorylation. Moreover, mass spectrometry analysis showed that 3’-dATP is the main active metabolite of NUC-7738. Transcriptome data analysis showed mitochondrial gene transcripts of electron transport chain (ETC) complexes were the most significantly altered in both 786-O and 769-P cell lines, with lower expression levels in response to NUC-7738 treatment. This was accompanied by downregulation of the protein expression of ETC complexes subunits. NUC-7738 induced the intrinsic pathway of apoptosis in these cells through the release of cytochrome c from mitochondria and the subsequent activation of caspases -9 and -7. These data suggest that NUC-7738 might inhibit tumour cells growth and proliferation through the inhibition of mitochondrial respiration and the subsequent induction of apoptosis. | en_US |
dc.language.iso | en | en_US |
dc.subject | Clear cell renal cell carcinoma | en_US |
dc.subject | 3'-deoxyadenosine | en_US |
dc.subject | AMPK | en_US |
dc.subject | OXPHOS | en_US |
dc.subject | Electron transport chain | en_US |
dc.subject | Polyadenylation | en_US |
dc.subject | Transcription | en_US |
dc.subject | Mitochondria | en_US |
dc.subject.lcc | RC280.K5K8 | |
dc.subject.lcsh | Renal cell carcinoma | en |
dc.title | Mechanisms of action of 3’-deoxyadenosine in treating clear cell renal cell carcinoma | en_US |
dc.type | Thesis | en_US |
dc.contributor.sponsor | University of St Andrews. School of Medicine | en_US |
dc.contributor.sponsor | NuCana PLC | en_US |
dc.contributor.sponsor | Council for At-Risk Academics (CARA) | en_US |
dc.type.qualificationlevel | Doctoral | en_US |
dc.type.qualificationname | PhD Doctor of Philosophy | en_US |
dc.publisher.institution | The University of St Andrews | en_US |
dc.rights.embargodate | ||
dc.rights.embargoreason | Thesis unavailable: permission not provided to allow public access | en |
dc.identifier.doi | https://doi.org/10.17630/sta/475 |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.